Physician profile
Katrina M Bassel
NPI 1366555385
$5,774.41
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $496 · 2021: $1,409 · 2022: $1,357 · 2023: $1,127 · 2024: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,808 · Education: $13.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,807.96 |
| Education | $13.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,147.83 | 2019-2024 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $315.65 | 2019-2024 | Gattex, Entyvio, Eohilia |
| Celgene Corporation | $275.37 | 2022-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $256.27 | 2021-2024 | Dificid, Zerbaxa, Recarbrio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.57 | 2019-2024 | Trulance |
| Gilead Sciences, INC. | $173.94 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $162.52 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $148.41 | 2020-2023 | |
| Janssen Biotech, INC. | $119.21 | 2022-2023 | Stelara, Simponi Aria, Remicade |
| Boston Scientific Corporation | $116.95 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Daiichi Sankyo INC. | $115.28 | 2020-2023 | Injectafer |
| Redhill Biopharma INC. | $78.38 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $72.15 | 2024 | |
| Intercept Pharmaceuticals, INC. | $70.43 | 2019-2021 | |
| Braintree Laboratories, INC. | $61.98 | 2021-2023 | Sutab |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $51.11 | 2019-2022 | |
| Amgen INC. | $41.43 | 2020-2023 | Amjevita, Avsola |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.06 | 2023 | Cyltezo |
| Vivus LLC | $38.08 | 2021-2023 | Pancreaze |
| Qol Medical, LLC | $38.03 | 2021 | |
| Shire North American Group INC | $31.73 | 2019 | |
| Medtronic, INC. | $30.50 | 2022 | |
| Fresenius Kabi USA, LLC | $30.09 | 2023 | Idacio |
| Ardelyx, INC. | $28.48 | 2023 | Ibsrela |
| Organon LLC | $25.04 | 2021-2022 | |
| Lilly USA, LLC | $22.72 | 2024 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $22.62 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.54 | 2023 | Andexxa |
| Celltrion USA INC. | $13.46 | 2024 | Zymfentra |
| Evoke Pharma, INC. | $13.40 | 2022 | |
| Ucb, INC. | $13.10 | 2019 | |
| Allergan, INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Bassel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.